Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ge healthcare as - gadoterinsyra - injektionsvätska, lösning - 0,5 mmol/ml - gadoterinsyra 279,32 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ge healthcare as - gadoterinsyra - injektionsvätska, lösning i förfylld spruta - 0,5 mmol/ml - gadoterinsyra 279,32 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cipla europe nv - bivalirudin - pulver till koncentrat till injektions-/infusionsvätska, lösning - 250 mg - bivalirudin 250 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - kaspofunginacetat - pulver till koncentrat till infusionsvätska, lösning - 70 mg - sackaros hjälpämne; mannitol hjälpämne; kaspofunginacetat 77,69 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orion corporation - kaspofunginacetat - pulver till koncentrat till infusionsvätska, lösning - 50 mg - mannitol hjälpämne; sackaros hjälpämne; kaspofunginacetat 55,52 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunsuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasisartrit arthritiscosentyx, ensamt eller i kombination med metotrexat (mtx), är indicerat för behandling av aktiv psoriasisartrit hos vuxna patienter, när svaret på tidigare sjukdomsmodifierande anti-reumatiska läkemedel (dmard) terapi har varit otillräcklig. axiell spondyloarthritis (axspa)ankyloserande spondylit (as, röntgen axiell spondyloarthritis)cosentyx är indicerat för behandling av aktiv ankyloserande spondylit hos vuxna som svarat otillräckligt för att konventionell terapi. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - svenska - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

gedeon richter plc - ibandronatnatriummonohydrat - filmdragerad tablett - 150 mg - ibandronatnatriummonohydrat 168,81 mg aktiv substans; laktosmonohydrat hjälpämne - ibandronat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - vorikonazol - filmdragerad tablett - 200 mg - vorikonazol 200 mg aktiv substans; laktosmonohydrat hjälpämne - vorikonazol